Standout Papers

<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors 1998 2026 2007 2016 1.7k
  1. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Science
  2. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  3. Biology of Gastrointestinal Stromal Tumors (2004)
    Christopher L. Corless, Jonathan A. Fletcher et al. Journal of Clinical Oncology
  4. The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy (1998)
    Jeffrey S. Ross, Jonathan A. Fletcher Stem Cells
  5. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT (2008)
    Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology
  6. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors (2006)
    Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology
  7. PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma (2000)
    Todd G. Kroll, Pasha Sarraf et al. Science
  8. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor (2008)
    Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology
  9. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients (1992)
    Tanya Basu, David H. Gutmann et al. Nature
  10. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group (2008)
    Michael C. Heinrich, Kouros Owzar et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 18 from Science/Nature 120 standout
Sub-graph 1 of 19

Citing Papers

Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
2017 Standout
34 intermediate papers

Works of Jonathan A. Fletcher being referenced

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
2014
Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases
2008
and 32 more

Author Peers

Author Last Decade Papers Cites
Jonathan A. Fletcher 10823 8303 7119 202 22.9k
Robert G. Maki 17885 7745 3888 377 25.7k
Michael C. Heinrich 17093 16713 6153 373 31.5k
Margaret von Mehren 10412 8993 2191 282 15.9k
Maria Dêbiec‐Rychter 7297 4051 2351 307 11.9k
Jayesh Desai 4816 1969 3363 317 12.9k
Alexander J. Lazar 8949 867 6383 442 20.4k
Silvana Pilotti 5255 838 5054 293 15.9k
Grant A. McArthur 5248 1462 14988 388 26.3k
Laura H. Tang 3870 1206 2617 288 15.2k
Lee J. Helman 4895 591 6891 203 14.1k

All Works

Loading papers...

Rankless by CCL
2026